Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Unknown 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Gynecologic 1Dermatologic 1Breast 1

Conditions

Pancreatic Neoplasms 9Colonic Neoplasms 5Ovarian Neoplasms 3Melanoma 3Colorectal Neoplasms 3Carcinoma, Hepatocellular 3Carcinoma 3Breast Neoplasms 3Stomach Neoplasms 2Liver Neoplasms 2Fibrolamellar hepatocellular carcinoma 2Esophageal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Adenocarcinoma 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neoplasms, Squamous Cell 1Neoplasms, Plasma Cell 1Neoplasm Metastasis 1Diabetes Mellitus, Insulin-Dependent, 12 1Chondrosarcoma 1Carcinoma, Transitional Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Merkel Cell 1Biliary Tract Neoplasms 1

Interventions

Sorafenib 68Bevacizumab 44Oxaliplatin 25Doxorubicin 22Gemcitabine 21Fluorouracil 21Radiosurgery 20Nivolumab 19durvalumab 18Radiofrequency Ablation 18pembrolizumab 17lenvatinib 17Cisplatin 17Capecitabine 17atezolizumab 14Leucovorin 14Hepatectomy 14Radiotherapy 12tremelimumab 10Irinotecan 10Drug Therapy 10Cyclophosphamide 10Carboplatin 10Blood Specimen Collection 10Ipilimumab 9regorafenib 8Liver Transplantation 8Everolimus 8Cryosurgery 8Chemotherapy, Adjuvant 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Liver Neoplasms × poly ICLC × Gastrointestinal × Clear all
NCT07430202 2026-05-06

A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1 Not yet recruiting
27 enrolled
Gastrointestinal

Fibrolamellar hepatocellular carcinoma, Carcinoma, Liver Neoplasms

NCT00553683 2014-01-14

Cyclophosphamide, Radiation Therapy, and Poly ICLC in Treating Patients With Unresectable, Recurrent, Primary, or Metastatic Liver Cancer

Rutgers, The State University of New Jersey

Phase 1/2 Unknown
50 enrolled
BreastDermatologicGastrointestinalGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Colonic Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡